Oruka Therapeutics, Inc.
ORKA
$29.91
$2.087.47%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -23.21% | -17.02% | 37.11% | -16.66% | -28.68% |
| Total Depreciation and Amortization | 5.26% | 18.75% | -13.51% | 68.18% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 150.26% | 17.50% | -26.18% | -59.49% | 1,427.87% |
| Change in Net Operating Assets | 73.70% | 24.56% | -160.27% | 151.72% | -192.51% |
| Cash from Operations | 6.67% | -10.91% | 13.32% | 13.45% | -152.13% |
| Capital Expenditure | -191.18% | -161.54% | 63.07% | 79.42% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -2,600.00% | -88.59% | 111.91% | -- | -- |
| Cash from Investing | -2,619.53% | -88.66% | 111.91% | -210,407.31% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 155,778.90% | -- | -- | -91.05% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -93.12% | 510.89% |
| Cash from Financing | 155,778.90% | -- | -- | -90.48% | 26,767.28% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 242.26% | -182.63% | 106.40% | -186.85% | 3,235.43% |